KARYOPHARM THERAPEUTICS INC's ticker is and the CUSIP is 48576U906. A total of 2 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $609,053 | +1848.5% | 702,000 | +3291.3% | 0.00% | – |
Q1 2024 | $31,257 | -59.7% | 20,700 | -76.9% | 0.00% | – |
Q4 2023 | $77,501 | -51.5% | 89,600 | -24.8% | 0.00% | -100.0% |
Q3 2023 | $159,728 | +17.6% | 119,200 | +57.0% | 0.00% | – |
Q2 2023 | $135,861 | +535.0% | 75,900 | +1280.0% | 0.00% | – |
Q1 2023 | $21,395 | -97.2% | 5,500 | -97.6% | 0.00% | -100.0% |
Q4 2022 | $769,080 | -44.1% | 226,200 | -10.2% | 0.00% | -33.3% |
Q3 2022 | $1,376,000 | +2.1% | 252,000 | -15.7% | 0.00% | +50.0% |
Q2 2022 | $1,348,000 | -37.8% | 298,800 | +1.7% | 0.00% | 0.0% |
Q1 2022 | $2,166,000 | +68.2% | 293,900 | +46.7% | 0.00% | +100.0% |
Q4 2021 | $1,288,000 | +157.6% | 200,300 | +133.2% | 0.00% | 0.0% |
Q3 2021 | $500,000 | -60.0% | 85,900 | -29.1% | 0.00% | -50.0% |
Q2 2021 | $1,250,000 | -7.7% | 121,100 | -5.9% | 0.00% | 0.0% |
Q1 2021 | $1,354,000 | -14.6% | 128,700 | +25.7% | 0.00% | -33.3% |
Q4 2020 | $1,585,000 | -28.3% | 102,400 | -32.4% | 0.00% | -57.1% |
Q3 2020 | $2,212,000 | +0.2% | 151,500 | +30.0% | 0.01% | -30.0% |
Q2 2020 | $2,207,000 | -7.6% | 116,500 | -6.3% | 0.01% | -47.4% |
Q1 2020 | $2,388,000 | -49.5% | 124,300 | -49.6% | 0.02% | -40.6% |
Q4 2019 | $4,729,000 | +3302.2% | 246,700 | +1613.2% | 0.03% | +3100.0% |
Q3 2019 | $139,000 | +414.8% | 14,400 | +220.0% | 0.00% | – |
Q2 2019 | $27,000 | -70.7% | 4,500 | -71.3% | 0.00% | -100.0% |
Q1 2019 | $92,000 | +80.4% | 15,700 | +190.7% | 0.00% | – |
Q4 2018 | $51,000 | -52.3% | 5,400 | -14.3% | 0.00% | -100.0% |
Q3 2018 | $107,000 | -8.5% | 6,300 | -8.7% | 0.00% | 0.0% |
Q2 2018 | $117,000 | -37.8% | 6,900 | -50.7% | 0.00% | -50.0% |
Q1 2018 | $188,000 | -54.8% | 14,000 | -67.7% | 0.00% | -33.3% |
Q4 2017 | $416,000 | -32.9% | 43,300 | -23.4% | 0.00% | -50.0% |
Q3 2017 | $620,000 | +50.1% | 56,500 | +23.9% | 0.01% | +50.0% |
Q2 2017 | $413,000 | -58.8% | 45,600 | -41.6% | 0.00% | -66.7% |
Q1 2017 | $1,003,000 | +591.7% | 78,100 | +407.1% | 0.01% | +1100.0% |
Q4 2016 | $145,000 | -26.8% | 15,400 | -24.5% | 0.00% | -50.0% |
Q3 2016 | $198,000 | +842.9% | 20,400 | +558.1% | 0.00% | – |
Q2 2016 | $21,000 | -89.6% | 3,100 | -86.3% | 0.00% | -100.0% |
Q1 2016 | $202,000 | -16.5% | 22,600 | +23.5% | 0.00% | 0.0% |
Q4 2015 | $242,000 | -60.6% | 18,300 | -68.6% | 0.00% | -62.5% |
Q3 2015 | $614,000 | +12180.0% | 58,300 | +29050.0% | 0.01% | – |
Q2 2015 | $5,000 | -92.5% | 200 | -90.9% | 0.00% | -100.0% |
Q1 2015 | $67,000 | +857.1% | 2,200 | +1000.0% | 0.00% | – |
Q4 2014 | $7,000 | -88.9% | 200 | -88.9% | 0.00% | -100.0% |
Q3 2014 | $63,000 | – | 1,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GROUP ONE TRADING, L.P. | 200 | $7,000 | 0.00% |
Citadel Advisors | 6,500 | $243,000 | 0.00% |